Last reviewed · How we verify

NCT02517931

Sphenopalatine Ganglion Block for Postdural Puncture Headache in the Emergency Department

Withdrawn NA Last updated 25 September 2019
What this trial tests

NA trial testing Sphenopalatine Ganglion Block in Postdural Puncture Headache. Withdrawn.

Timeline
1 January 2019
Primary endpoint
23 September 2019
23 September 2019

Quick facts

Lead sponsorUniversity of Arkansas
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeother
Start date1 January 2019
Primary completion23 September 2019
Estimated completion23 September 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Arkansas

Who can join

18 and older, any sex, with Postdural Puncture Headache. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates sphenopalatine ganglion block (SPGB) for the treatment of postdural puncture headache (PDPH) in the emergency department (ED). Half of the patients will receive a true nerve block with lidocaine and bupivacaine. The other half will receive a placebo nerve block.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sphenopalatine Ganglion Block

Trials testing the same drug.

Other recruiting trials for Postdural Puncture Headache

Currently open trials in the same condition.

Other University of Arkansas trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02517931.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing